GlassScriptPhysician profile
Yishu Han
NPI 1619505989
$1,375.85
in general payments reported to CMS, 2019-2025
17 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $96.96 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $284.16 | 2025 | |
| Akebia Therapeutics INC | $191.39 | 2025 | Vafseo |
| Travere Therapeutics, INC. | $158.34 | 2025 | Filspari |
| Amgen INC. | $103.95 | 2024-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $89.21 | 2024-2025 | Farxiga |
| Ardelyx, INC. | $83.46 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $69.53 | 2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $68.61 | 2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $53.91 | 2025 | |
| Fresenius USA Marketing, INC. | $45.74 | 2025 | Velphoro |
| Apellis Pharmaceuticals, INC. | $45.30 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $39.82 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.65 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $34.74 | 2025 | Jynarque |
| Kyowa Kirin, INC. | $27.15 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.76 | 2025 | |
| Mallinckrodt Hospital Products INC. | $18.13 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yishu Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.